Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
DXCM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$57.52 - $93.25
Previous CloseN/A
Volume488.69K
Average Volume (3M)3.43M
Market Cap
$31.44B
Enterprise Value$35.28B
Total Cash (Recent Filing)$2.93B
Total Debt (Recent Filing)$2.58B
Price to Earnings (P/E)56.1
Beta1.10
Next Earnings
Oct 23, 2025EPS Estimate
0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding392,155,270
10 Day Avg. Volume4,970,398
30 Day Avg. Volume3,426,486
Financial Highlights & Ratios
PEG Ratio39.32
Price to Book (P/B)14.97
Price to Sales (P/S)7.80
P/FCF Ratio49.89
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue8.20
Enterprise Value/Gross Profit13.96
Enterprise Value/Ebitda33.95
Forecast
1Y Price Target
$100.38Price Target Upside25.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
Bulls Say, Bears Say
Bulls Say
EarningsDXCM reported a solid top-line beat in the second quarter with sales of $1.16 billion, exceeding consensus expectations by 3%.
LeadershipThe appointment of Jake Leach as CEO is seen as a strategic move due to his wealth of industry experience and deep understanding of DXCM.
Product LaunchThe upcoming launch of DXCM's G7 15-day sensor is expected to be a significant catalyst for growth.
Bears Say
GuidanceThe updated guidance is slightly below investor expectations, seen as conservative.
Market ShareDXCM doesn’t expect to lose US patient share next year despite Libre expecting to gain US revenue share.
Stock PerformanceDespite a solid $33 million beat in the second quarter, the stock traded off 10% post earnings.
Dexcom News
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $57.52 and its highest was $93.25 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $31.44B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Oct 23, 2025 which is in 70 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Jul 30, 2025. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.444 by $0.036.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.57.
How many shares outstanding does Dexcom have?
Dexcom has 392,155,270 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.48 in its last earnings report, beating expectations of $0.444. Following the earnings report the stock price went down -9.308%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DXCM
Dexcom Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$100.38 (25.21% Upside)
$100.38 (25.21% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 68%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $688.2 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.48%
12-Months-Change
Fundamentals
Return on Equity
22.83%
Trailing 12-Months
Asset Growth
7.76%
Trailing 12-Months
Company Description
Dexcom
Dexcom, Inc. is a global leader in continuous glucose monitoring (CGM) technology, primarily serving individuals with diabetes. Founded in 1999 and headquartered in San Diego, California, Dexcom develops and manufactures state-of-the-art CGM systems that provide real-time glucose readings, allowing users to manage their diabetes more effectively. The company's core products include the Dexcom G6 and G7 CGM systems, which are designed to provide accurate, timely glucose data to patients and healthcare providers, facilitating better decision-making regarding insulin dosing and lifestyle management.
DXCM Company Deck
DXCM Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, expansion in type 2 non-insulin coverage, and international successes. However, challenges such as gross margin decline and inventory management were noted. Overall, the highlights indicate a strong positive trajectory for DexCom.View all DXCM earnings summariesDXCM Revenue Breakdown
71.65% U.S.
28.35% Outside of the U.S.
DXCM Stock 12 Month Forecast
Average Price Target
$100.38
▲(25.21% Upside)
Technical Analysis
Ownership Overview
0.47% Insiders
29.44% Mutual Funds
1.01% Other Institutional Investors
40.48% Public Companies and Individual Investors